From 2024 to 2028, France shows a steady increase in the forecasted use of medicines for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD), beginning at 95.1 units in 2024 and rising to 102.3 units by 2028. The yearly growth rate from 2024 to 2025 is 2.0%, with a consistent increase continuing in the subsequent years. The compound annual growth rate (CAGR) over this period is approximately 1.8%.
Points of interest for future trends:
- Monitoring innovations in medication options which may influence existing demand.
- Observing potential policy changes in healthcare that could impact accessibility or affordability.
- Assessing demographic shifts, such as aging populations, that may elevate demand.
- Tracking advancements in alternative treatments that might alter the upward trajectory in medicine usage.
